Gainers
- BIMI International BIMI stock increased by 17.6% to $1.4 during Wednesday's after-market session. This security traded at a volume of 173.1K shares come close, making up 23.1% of its average volume over the last 100 days. The company's market cap stands at $11.9 million.
- BioSig Technologies BSGM shares increased by 10.09% to $1.2. The market value of their outstanding shares is at $42.3 million.
- Satsuma Pharmaceuticals STSA stock increased by 10.05% to $4.16. The market value of their outstanding shares is at $131.1 million. As per the news, the Q4 earnings report came out yesterday.
- INmune Bio INMB shares increased by 9.89% to $8.0. The company's market cap stands at $142.9 million.
- Stealth BioTherapeutics MITO stock rose 9.39% to $0.63. The company's market cap stands at $36.2 million.
- Salarius Pharmaceuticals SLRX shares rose 9.1% to $0.39. The market value of their outstanding shares is at $17.6 million. As per the press release, Q4 earnings came out 4 days ago.
Losers
- Impel NeuroPharma IMPL shares declined by 13.4% to $5.74 during Wednesday's after-market session. The market value of their outstanding shares is at $132.2 million.
- Sunshine Biopharma SBFM shares fell 7.63% to $3.03. The company's market cap stands at $13.5 million.
- Myovant Sciences MYOV shares declined by 5.78% to $11.91. The company's market cap stands at $1.1 billion.
- Codex DNA DNAY shares fell 5.75% to $9.35. The company's market cap stands at $274.0 million.
- Alaunos Therapeutics TCRT stock decreased by 5.65% to $0.69. At the close, Alaunos Therapeutics's trading volume reached 73.6K shares. This is 3.6% of its average volume over the last 100 days. The company's market cap stands at $148.0 million.
- Homology Medicines FIXX shares fell 5.1% to $2.98. The company's market cap stands at $170.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in